Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVE: Teclistamab or Talquetamab + Daratumumab for High-Risk Smoldering Myeloma
NCT06100237Phase 2Recruiting
- Start
- Dec 2023
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab, talquetamab in smoldering multiple myeloma (SMM). Started Dec 2023; status: recruiting.
02
Drugs
teclistamabtalquetamab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT06100237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06100237.